MLTX
Income statement / Annual
Last year (2025), MoonLake Immunotherapeutics's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, MoonLake Immunotherapeutics's net income was -$227.32 M.
See MoonLake Immunotherapeutics,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.62 M
|
$0.00
|
$0.00
|
$0.00
|
$4.97 K
|
$0.00
|
| Gross Profit |
-$2.62 M
|
$0.00
|
$0.00
|
$0.00
|
-$4.97 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$202.86 M
|
$112.77 M
|
$31.80 M
|
$42.05 M
|
$35.52 M
|
$0.00
|
| General & Administrative Expenses |
$41.97 M
|
$30.32 M
|
$22.32 M
|
$23.01 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$41.97 M
|
$30.32 M
|
$22.32 M
|
$23.01 M
|
$18.05 M
|
$105.76 K
|
| Other Expenses |
-$2.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$242.22 M
|
$143.09 M
|
$54.12 M
|
$65.06 M
|
$53.57 M
|
$105.76 K
|
| Cost And Expenses |
$244.83 M
|
$143.09 M
|
$54.12 M
|
$65.06 M
|
$53.58 M
|
$105.76 K
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$14.92 K
|
| Interest Expense |
$7.25 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.62 M
|
$1.38 M
|
$370.32 K
|
$164.78 K
|
$4.97 K
|
$0.00
|
| EBITDA |
-$219.85 M |
-$119.58 M |
-$43.61 M |
-$64.30 M |
-$53.63 M |
-$90.84 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$15.12 M
|
$22.13 M
|
$10.14 M
|
$591.73 K
|
-$61.85 K
|
$14.92 K
|
| Income Before Tax |
-$229.71 M
|
-$120.96 M
|
-$43.98 M
|
-$64.47 M
|
-$53.64 M
|
-$90.84 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$611.00 K
|
$282.20 K
|
$94.39 K
|
$36.37 K
|
$4.76 K
|
$0.00
|
| Net Income |
-$227.32 M
|
-$118.94 M
|
-$36.01 M
|
-$49.97 M
|
-$53.64 M
|
-$90.84 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.53 |
-1.89 |
-0.73 |
-2.2 |
-1.45 |
-0.0061 |
| EPS Diluted |
-3.53 |
-1.89 |
-0.73 |
-2.2 |
-1.45 |
-0.0061 |
| Weighted Average Shares Out |
$64.46 M
|
$62.87 M
|
$49.12 M
|
$29.36 M
|
$36.93 M
|
$14.81 M
|
| Weighted Average Shares Out Diluted |
$64.46 M
|
$62.87 M
|
$49.12 M
|
$29.36 M
|
$36.93 M
|
$14.81 M
|
| Link |
|
|
|
|
|
|
